{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060660","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.294334+00:00","generated_at":"2026-06-08T09:50:20.160027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Beam Q3 2023: net loss $96.1M, Lilly deal up to $600M, pipeline on track","bullets":["Net loss of $96.1M ($1.22 per share) vs $109.6M ($1.56) in Q3 2022; R&D $100M, G&A $25.4M.","Cash and securities $1.0B as of Sep 30, 2023; expected runway into H2 2026 with Lilly proceeds.","Lilly acquired opt-in rights to Verve's CV programs for $200M upfront + $50M equity + up to $350M milestones ($600M total).","BEAM-101 first patient treatment by year-end 2023; initial data on multiple patients in 2024.","BEAM-302 regulatory filing in Q1 2024; BEAM-301 IND in H1 2024; BEAM-201 initial data in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060660","json":"https://secwatch.observer/filing/0000950170-23-060660.json","markdown":"https://secwatch.observer/filing/0000950170-23-060660.md","text":"https://secwatch.observer/filing/0000950170-23-060660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023060660/0000950170-23-060660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023060660/beam-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:50:20.160027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"286a38d8999e2b3ecccd5daa1027dd790994eb85","claim":"Beam Therapeutics Inc. reported financial results for the third quarter 2023.","evidence_excerpt":"On November 8, 2023, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023060660/0000950170-23-060660-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}